Disseminated Mycobacterium avium and Talaromyces Marneffei coinfection in a patient of misdiagnosed tuberculosis and the challenges: a case report.

Disseminated Mycobacterium avium and Talaromyces Marneffei coinfection in a patient of misdiagnosed tuberculosis and the challenges: a case report.

Publication date: Oct 31, 2025

Mycobacterium avium (M. avium) is emerging as an opportunistic pathogen and has been grouped with the nontuberculosis mycobacteria (NTM). Tuberculosis (TB), caused by Mycobacterium tuberculosis, primarily affects elderly individuals with chronic lung disease and remains one of the leading causes of death in many regions worldwide. Distinguishing between NTM infection and TB is challenging due to similar clinical manifestations and histopathological characteristics. Talaromyces marneffei (T. marneffei) is a pathogenic fungus causing devastating infection, primarily in immunocompromised individuals. Few reports describe disseminated co-infection of M. avium and T. marneffei in HIV-negative persons. Herein, we present a case of an HIV-negative Chinese woman who initially presented with chronic cough, sputum production, and recurrent low-grade fever, which was initially misdiagnosed as TB. After three years of anti-TB treatment, her situation progressed, and she developed multiple subcutaneous abscesses throughout the body, including the brain. Subsequent bacterial culture and molecular diagnostic techniques confirmed the presence of NTM, specifically identified as M. avium. However, despite receiving anti-M. avium therapy remained ineffective until co-infection with T. marneffei was eventually diagnosed. The patient responded well to anti-M. avium therapy combined with antifungal agents after two weeks. Unfortunately, she was lost during the follow-up. Strict adherence to the established clinical diagnostic guidelines for tuberculosis is essential. Early implementation of ‌microbial culture and molecular diagnostic tools plays a critical role in distinguishing TB from NTM infections, particularly in patients who do not respond adequately to anti-tuberculosis therapies. In addition, clinicians should remain vigilant for potential co-infections when inflammatory markers fail to decline or disease progression continues despite adequate anti-infective treatment.

Open Access PDF

Concepts Keywords
Chinese Antitubercular Agents
Elderly Antitubercular Agents
Mycobacteria Case report
Tuberculosis Co-infection
Worldwide Coinfection
Diagnostic Errors
Female
Humans
Middle Aged
Mycobacterium avium
Mycobacterium avium
Mycoses
Talaromyces
Talaromyces marneffei
Tuberculosis
Tuberculosis

Semantics

Type Source Name
disease MESH coinfection
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO opportunistic pathogen
disease MESH lung disease
disease MESH causes of death
disease MESH infection
disease IDO production
disease MESH abscesses
disease IDO role
disease MESH disease progression
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH death
disease IDO pathogen
disease MESH acquired immunodeficiency syndrome
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
disease MESH cerebral abscesses
disease MESH chest pain
disease MESH pulmonary tuberculosis
disease MESH pleuritis
disease MESH lymph node tuberculosis
disease MESH inflammation
disease MESH ulcer
drug DRUGBANK Amikacin
drug DRUGBANK Moxifloxacin
drug DRUGBANK Clofazimine
drug DRUGBANK Linezolid
disease MESH hallucinations
disease IDO history
disease MESH pallor
disease MESH leukocytosis
disease IDO blood
disease MESH anemia
drug DRUGBANK Creatinine
disease MESH necrosis
disease MESH pericardial effusion
drug DRUGBANK Silver
disease MESH pus
drug DRUGBANK Itraconazole
drug DRUGBANK Clarithromycin
drug DRUGBANK Ethambutol
drug DRUGBANK Doxycycline
drug DRUGBANK L-Leucine
disease MESH weight loss
disease MESH granulomas
disease MESH complications
disease MESH misdiagnosis
drug DRUGBANK Trestolone
drug DRUGBANK Gold
disease MESH missed diagnosis
disease MESH pleural effusion
disease MESH edema
drug DRUGBANK Flunarizine
drug DRUGBANK Rifamycin
drug DRUGBANK Isoniazid
disease MESH lymphadenopathy
disease MESH erythema
disease MESH delayed treatment
disease IDO site
drug DRUGBANK Dextrose unspecified form
disease IDO colony
disease MESH sweet’s syndrome
disease MESH salmonellosis
disease IDO acquired immunodeficiency
disease MESH immunocompromised patients
disease MESH pulmonary aspergillosis
disease MESH Clinical significance
disease MESH Talaromyces Marneffei infection
drug DRUGBANK Guanosine
disease MESH Mycoses
drug DRUGBANK Myricetin
disease MESH opportunistic infections
drug DRUGBANK Amphotericin B

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *